(Total Views: 365)
Posted On: 08/12/2021 3:54:35 PM
Post# of 1460
A good post copied from IHUB,
Fletch
falconer66a Thursday, 08/12/21 10:59:31 AM
Re: georgejjl post# 325482 0
Post # of 325566
No competition; nothing else can work.
Quote:
Anavex is the ONLY drug to show actual IMPROVEMENT for longer than a year from baseline for the treatment of Alzheimer’s disease and Parkinson’s disease.
This greatly separates blarcamesine from the few other drugs approved for and used to treat both Alzheimer’s and Parkinson’s disease. There are a few; for Alzheimer’s, Aricept is the most prominent. But it merely slows, for a time, the lethal progression of the disease. Without exception, those with Alzheimer’s, taking Aricept will eventually experience the fateful, even lethal outcomes of the disease. For a time, at the start of therapy, their progression will be only moderated or delayed.
This is crucial. Aricept does not, cannot terminate the root causes of Alzheimer’s. It merely smothers, for a time, the bad symptoms. The underlying pathogenic processes continue, sooner or later overwhelming the ability of Aricept to douse the increasingly bad symptoms.
This is where blarcamesine is utterly different. By its favorable activation of the sigma-1 receptor protein, it causes it to resume it’s proper functions of modulating homeostatic processes, including those that facilitate proper folding of proteins (enzymes), which then go on to healthfully modulate the chemical reactions within neurons.
At the sigma-1 receptor protein, blarcamesine works “upstream” in the flow of chemical reactions and processes that healthfully maintain cell biology. Blarcamesine works at the “headwaters” of the many reaction pathways, causing the “downstream” processes to work as they should, as directed by the genome.
And this, of course, accounts for blarcamesine’s unique ability to reverse the progression of Alzheimer’s (and other CNS diseases). Without effective, restorative activation of the sigma-1 receptor protein, the underlying pathogenic processes of Alzheimer’s and other CNS diseases will be unabated.
And, of course, this same mechanism, blarcamesine activation of the sigma-1 receptor, will prevent the onset of Alzheimer’s. Blarcamesine will not only effectively treat the disease, restoring to some degree (great or small) cognition, but will prevent its onset; the great prophylaxis factor.
Fletch
falconer66a Thursday, 08/12/21 10:59:31 AM
Re: georgejjl post# 325482 0
Post # of 325566
No competition; nothing else can work.
Quote:
Anavex is the ONLY drug to show actual IMPROVEMENT for longer than a year from baseline for the treatment of Alzheimer’s disease and Parkinson’s disease.
This greatly separates blarcamesine from the few other drugs approved for and used to treat both Alzheimer’s and Parkinson’s disease. There are a few; for Alzheimer’s, Aricept is the most prominent. But it merely slows, for a time, the lethal progression of the disease. Without exception, those with Alzheimer’s, taking Aricept will eventually experience the fateful, even lethal outcomes of the disease. For a time, at the start of therapy, their progression will be only moderated or delayed.
This is crucial. Aricept does not, cannot terminate the root causes of Alzheimer’s. It merely smothers, for a time, the bad symptoms. The underlying pathogenic processes continue, sooner or later overwhelming the ability of Aricept to douse the increasingly bad symptoms.
This is where blarcamesine is utterly different. By its favorable activation of the sigma-1 receptor protein, it causes it to resume it’s proper functions of modulating homeostatic processes, including those that facilitate proper folding of proteins (enzymes), which then go on to healthfully modulate the chemical reactions within neurons.
At the sigma-1 receptor protein, blarcamesine works “upstream” in the flow of chemical reactions and processes that healthfully maintain cell biology. Blarcamesine works at the “headwaters” of the many reaction pathways, causing the “downstream” processes to work as they should, as directed by the genome.
And this, of course, accounts for blarcamesine’s unique ability to reverse the progression of Alzheimer’s (and other CNS diseases). Without effective, restorative activation of the sigma-1 receptor protein, the underlying pathogenic processes of Alzheimer’s and other CNS diseases will be unabated.
And, of course, this same mechanism, blarcamesine activation of the sigma-1 receptor, will prevent the onset of Alzheimer’s. Blarcamesine will not only effectively treat the disease, restoring to some degree (great or small) cognition, but will prevent its onset; the great prophylaxis factor.
(2)
(0)Scroll down for more posts ▼
